CS
DAWN

Candriam SCA’s Day One Biopharmaceuticals DAWN Stock Holding History

Candriam SCA’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-290,014
Closed -$4.04M – 680
2024
Q3 		$4.04M Hold
290,014
– – 0.02% 402
2024
Q2 		$4M Hold
290,014
– – 0.02% 372
2024
Q1 		$4.79M Hold
290,014
– – 0.03% 351
2023
Q4 		$4.23M Hold
290,014
– – 0.03% 353
2023
Q3 		$3.56M Hold
290,014
– – 0.03% 352
2023
Q2 		$3.46M Buy
290,014
+99,821
+52% +$1.3M 0.03% 398
2023
Q1 		$2.34M Buy
+190,193
New +$3.72M 0.02% 540

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Candriam SCA's DAWN Position: Q4 2024 in Review

Candriam SCA sold out of Day One Biopharmaceuticals (DAWN) in Q4 2024, closing a stake of 290,014 shares — an estimated $4.04M sold.

Candriam SCA first reported a position in DAWN in Q1 2023 and held it in 7 quarters. The position peaked at $4.79M in Q1 2024. 164 funds tracked by Wall St. Rank hold DAWN as of Q4 2024.

  • Candriam SCA reported no remaining Day One Biopharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Candriam SCA sold 290,014 Day One Biopharmaceuticals shares in Q4 2024, an estimated $4.04M.
  • Candriam SCA first reported a position in Day One Biopharmaceuticals in Q1 2023 and held it in 7 quarters.
  • Candriam SCA's Day One Biopharmaceuticals position peaked at $4.79M in Q1 2024.
  • 164 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2024.

Based on Candriam SCA's 13F filing for Q4 2024, filed 7 Feb 2025.